Helicobacter pylori infectious disease
Therapeutic area
Infectious Disease
Rare disease
No
- Definition
- Infections with organisms of the genus HELICOBACTER, particularly, in humans, HELICOBACTER PYLORI. The clinical manifestations are focused in the stomach, usually the gastric mucosa and antrum, and the upper duodenum. This infection plays a major role in the pathogenesis of type B gastritis and peptic ulcer disease.
- Genetic basis
- No
- Non-human condition
- No
- Rare disease
- No
- Listing at source
- Listed
- Condition name
- Helicobacter pylori infectious disease
- Therapeutic area
- Infectious Disease
- Helicobacter pylori infectious disease
- Helicobacter pylori caused disease or disorder
- Helicobacter pylori disease or disorder
- Helicobacter infection
- Helicobacter pylori infection, susceptibility to
- infection, Helicobacter
- infections, Helicobacter
- Disease mechanisms
- Acquired
- All therapeutic areas
- Infectious Disease
- Severity
- Severe
- MONDO ID
- MONDO:0006781
- Parent condition
- MONDO:0021678
Related records
Broader conditions (7)
- Bacterial infectious disease
- Disease
- Disease by etiologic mechanism
- Disease of primarily extrinsic mechanism
- Gram-negative bacterial infections
- Human disease
- Infectious disease
Trials (481)
- 10 vs 14 Days Triple Therapy : H.Pylori Infection Eradication
- 10-day Versus 14-day Concomitant PAMC as First-line Treatment Strategy for the Eradication of H. Pylori Infection
- 13-C Urea Breath Test Using BreathID System and PPIs (Proton Pump Inhibitors)
- 14-day Double Therapy Versus Bismuth Quadruple Therapy in First-line Treatment of Helicobacter Pylori Infection
- 14-day Quadruple Hybrid vs. Concomitant Therapies for Helicobacter Pylori Eradication
- 15-day Sequential Therapy for Helicobacter Pylori Infection in Korea
- 5 Day Concomitant Versus 10 Day Sequential Therapy for Eradication of H. Pylori Infection
- 7 Days vs. 14 Days of Vonoprazan-based Triple Therapy for H. Pylori Eradication
- A "Screen and Treat" Helicobacter Pylori Eradication Trial in Adolescents in Three Regions of Chile
- A Clinical Trial on the Efficacy of Gastric Probiotics in the Treatment of Helicobacter Pylori Infection
- A Comparison of Four Different Treatment Regimens of Helicobacter Pylori in Chinese Children
- A Phase 1 Study to Evaluate PK Profile of Multiple Oral Administrations of TNP-2092 Capsules in Healthy Subjects
- A Phase 3 Study to Evaluate the Efficacy and Safety of Triple Therapy With CJ-12420 in H. Pylori Positive Patients
- A Pilot Study of a 14-day Modified Sequential Therapy for Helicobacter Pylori Infection
- A RCT of the Efficacy of Vonoprazan 20mg QD in the Treatment of Helicobacter Pylori Infection
- A RCT of Triple Therapy With Proton Pump Inhibitor vs Vonoprazan for Helicobacter Pylori Gastritis
- A Real World Study of Bismuth Colloidal Pectin Granules Quadruple Therapy for H. Pylori Eradication
- A Study About the Selection of Time for Retreatment of Helicobacter Pylori After Eradication Failure
- A Study of the Safety of Vonoprazan Exposure in Pregnant Women and Their Offspring
- A Study on Eradication Rate of Triple Therapy According to Treatment Period and CYP2C19 Polymorphisms in H.Pylori Patients
Approved drugs (1)
- UREA C 13
Drugs in development (32)
- Acetazolamide Phase 2
- Amoxicillin Phase 3
- Bismuth subcitrate Phase 3
- Bismuth subcitrate potassium Phase 3
- Bismuth subsalicylate Phase 3
- Cholecalciferol Phase 3
- Clarithromycin Phase 3
- Clavulanic acid Phase 3
- Esomeprazole Phase 3
- Ferric pyrophosphate Phase 1
- Ferrous fumarate Phase 1
- Gemifloxacin Phase 3
- Lansoprazole Phase 3
- Levofloxacin Phase 3
- Metronidazole Phase 3
- Moxifloxacin Phase 3
- Nitazoxanide Phase 3
- Omeprazole Phase 3
- Pantoprazole Phase 2
- Rabeprazole Phase 3
Other linked drugs (5)
- Diosmin
- Furazolidone
- Polaprezinc
- Rebamipide
- UREA C 14